A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

MJ Seckl; C Ottensmeier; M Cullen; P Schmid; L James; C Wadsworth; H Farrant; D Muthukumar; J Thompson; S Harden; G Middleton; K Fife; B Crosse; P Taylor; I Khan

Back

A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

Journal article

Peer reviewed

A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

MJ Seckl, C Ottensmeier, M Cullen, P Schmid, L James, C Wadsworth, H Farrant, D Muthukumar, J Thompson, S Harden, …

JOURNAL OF THORACIC ONCOLOGY, Vol.8, pp.S219-S219

01/11/2013

Abstract

Science & Technology

Life Sciences & Biomedicine

Oncology

Respiratory System

SCLC

pravastatin

phase III trial

placebo controlled

Files and links (1)

url

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000339624901023&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11d2a86992e85fb529977dad66a846d5View

Author

Metrics

22 Record Views

Details

Title: A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)
Creators: MJ Seckl
C Ottensmeier
M Cullen
P Schmid
L James
C Wadsworth
H Farrant
D Muthukumar
J Thompson
S Harden
G Middleton
K Fife
B Crosse
P Taylor
I Khan
Publication Details: JOURNAL OF THORACIC ONCOLOGY, Vol.8, pp.S219-S219
Publisher: LIPPINCOTT WILLIAMS & WILKINS
Date published: 01/11/2013
Date submitted: 17/05/2017
Identifiers: 99511204502346
Academic Unit: University of Surrey
Language: English
Resource Type: Journal article

A MULTICENTER PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF PRAVASTATIN ADDED TO FIRST-LINE STANDARD CHEMOTHERAPY IN PATIENTS WITH SMALL CELL LUNG CANCER (SCLC)

Abstract

Files and links (1)

Metrics

Details

Usage Policy